Education
About Us
Working with TipRanks
Follow Us
Noxopharm Ltd. (AU:NOX)
ASX:NOX
NOX Stock Chart & Stats
AU$0.09
>-AU$0.01(-8.99%)
At close: 4:00 PM EST
AU$0.09
>-AU$0.01(-8.99%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.14
Previous CloseN/A
Volume154.85K
Average Volume (3M)123.50K
Market Cap
AU$18.43M
Enterprise ValueAU$22.59M
Total Cash (Recent Filing)AU$1.55M
Total Debt (Recent Filing)AU$2.48M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding307,237,950
10 Day Avg. Volume89,571
30 Day Avg. Volume123,503
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)22.89
Price to Sales (P/S)5.60
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Oncology PipelineNoxopharm's clear strategic focus on oncology and proprietary small-molecule platforms is a durable business-strength. A specialized platform aimed at enhancing radiotherapy and immuno-oncology creates technical differentiation, supports multiple candidate programs, and improves partnership and licensing prospects over the medium term.
Revenue Recovery TrendA ~20% revenue rebound in 2025, after prior declines, indicates emerging commercial or milestone-related traction. If sustained, this trend can help fund development activities, validate parts of the business model, and reduce absolute reliance on external capital over the next several quarters.
Improving Free Cash Flow Vs Prior YearAn improving free cash flow trajectory, even from negative levels, suggests operational progress or timing of receipts. Continued improvement can materially extend runway, lower near-term financing needs, and demonstrate management's ability to tighten operations or monetize assets over the coming 2-6 months.
Bears Say
Persistent Negative ProfitabilityRepeated negative gross profit and sizable operating losses indicate the core business has not reached economic sustainability. Persistent unprofitability drains equity and hampers reinvestment capacity, forcing reliance on financing and constraining long-term margin improvement absent structural change to operations or revenue mix.
Heavy Cash Burn And Funding RelianceConsistent negative operating and free cash flow mean the company depends on external funding to sustain R&D and trials. That reliance raises dilution and refinancing risks, limits strategic optionality, and can impede multi-year clinical development plans if capital access tightens.
Weakened Balance Sheet And High LeverageA materially weakened balance sheet with debt about 3.6x equity reduces financial flexibility and raises solvency and refinancing risk. High leverage increases funding costs and can constrain the company's ability to finance clinical programs or attract partners without significant dilution or onerous terms.
Noxopharm Ltd. News
NOX FAQ
What was Noxopharm Ltd.’s price range in the past 12 months?
Noxopharm Ltd. lowest share price was AU$0.04 and its highest was AU$0.14 in the past 12 months.
What is Noxopharm Ltd.’s market cap?
Noxopharm Ltd.’s market cap is AU$18.43M.
When is Noxopharm Ltd.’s upcoming earnings report date?
Noxopharm Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 163 days.
How were Noxopharm Ltd.’s earnings last quarter?
Noxopharm Ltd. released its earnings results on Mar 03, 2026. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Noxopharm Ltd. overvalued?
According to Wall Street analysts Noxopharm Ltd.’s price is currently Overvalued.
Does Noxopharm Ltd. pay dividends?
Noxopharm Ltd. does not currently pay dividends.
What is Noxopharm Ltd.’s EPS estimate?
Noxopharm Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Noxopharm Ltd. have?
Noxopharm Ltd. has 307,237,950 shares outstanding.
What happened to Noxopharm Ltd.’s price movement after its last earnings report?
Noxopharm Ltd. reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.615%.
Which hedge fund is a major shareholder of Noxopharm Ltd.?
Currently, no hedge funds are holding shares in AU:NOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Noxopharm Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.50%
12-Months-Change
Fundamentals
Return on Equity
-157.93%
Trailing 12-Months
Asset Growth
-32.46%
Trailing 12-Months
Company Description
Noxopharm Ltd.
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Chimeric Therapeutics Ltd.
―
EZZ Life Science Holdings Ltd.
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―